Novo acquires Xellia Pharmaceuticals for $700 million

Novo A/S, the financing entity that is at the apex of Denmark’s pharmaceutical industry, has acquired all the share capital of Xellia Pharmaceuticals AS of Norway for about $700 million. One of the sellers was Britain’s 3i Group Plc.